Please login to the form below

Not currently logged in
Email:
Password:

Jorge Mestre-Ferrandiz to lead Office of Health Economics' consultancy division

Takes on newly-created position as OHE Consulting seeks expansion

Jorge Mestre-Ferrandiz - Office Health EconomicsThe Office of Health Economics (OHE) has appointed Dr Jorge Mestre-Ferrandiz as the first director of OHE Consulting – the organisation's consultancy division.

Mestre-Ferrandiz will lead the division's efforts to provide research-led consultancy in the health and life sciences economics and policy as it attempts to win external funding as part of plans to expand its operations.

He is in the sixth year of his second spell with the OHE, having previously worked at the research firm from 2001 to 2005 before spending a year at Spanish pharmaceutical trade association Farmaindustria.

He moved back to UK-based OHE in 2006, however, rejoining as a senior economist. In his new role Mestre-Ferrandiz will be responsible for all aspects of the OHE's consultancy business, including marketing, business development and project management.

He will also continue to contribute to all other OHE activities, including advising the UK pharma body the ABPI, as well as conducting and publishing his own research.

Mestre-Ferrandiz said: “I am confident that our experienced and highly skilled team of health economists will be a great draw for those looking to further their understanding of the health and life-sciences landscape and I am pleased I will be still be contributing personally as an economist to on-going projects.”

OHE Consultancy was set up in 2002 as an offshoot of the 50-year old OHE, which is funded by research grants and consultancy revenues from sources such as the ABPI, Department of Health, National Institute of Health Research and Medical Research Council.

17th July 2012

Share

Related Hub content

    Your search did not contain any words. Please try again.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Research Partnership

We are one of the largest independent healthcare market research and consulting agencies in the world. Trusted partner to the...

Latest intelligence

More of the same: The importance of strategic communications planning for biosimilar entry
GCI Health's Hannah Morris considers the importance of strategic communications planning for biosimilar entry, a market anticipated to deliver between €8-26bn in savings across the European Union by 2020....
Online Physician Communities
How can pharma realise the power of digital?
Firstly, by making it owned and driven by the most senior leadership team in the business...
Remapping the market: Does Pharma's global model need a shake up?
For patients, carers and professionals, wherever they are in the world, digital technology is inherent in their everyday lives. Digital is, so to speak, a global language. The success of...